Pfizer loses bid to block generic drug
- Share via
The Supreme Court turned down an appeal by Pfizer Inc. aimed at preventing the sale of a generic version of Norvasc, its bestselling drug for high blood pressure.
The New York-based pharmaceutical firm had asked the court to overturn an appeals court ruling this year that its patent was invalid.
The case began when Apotex, based in Winnipeg, Canada, challenged Pfizer’s patent in 2003, requesting that regulators allow it to sell a generic version of the drug.
Pfizer’s patent on Norvasc expired last week.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
